Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 19/4/2018
SIETES contiene 92257 citas

 
 
 1 a 11 de 11 
Presentar resultados
Seleccionar todas
3.Enlace a cita original
Mackenzie IS, MacDonald TM, Shakir S, Dryburgh M, Mantay BJ, McDonnell P, Layton D. Influenza H1N1 (swine flu) vaccination: a safety surveillance feasibility study using self-reporting of serious adverse events and prengnacy outcomes. Br J Clin Pharmacol 2012;73:801-11. [Ref.ID 92797]
4. Cita con resumen
Lynn E, Layton D, Shakir S. New postgraduate qualifications in pharmacovigilance from The Drug Safety Research Unit in the UK. Drug Saf 2011;34:89-91. [Ref.ID 89980]
5. Cita con resumen
Cooper AJP, Lettis S, Chapman CL, Evans SJW, Waller PC, Shakir S, Payvandi N, Murray AB. Developing tools for the safety specification in risk management plans: lessons learned from a pilot project. Pharmacoepidemiol Drug Saf 2008;17:45-454. [Ref.ID 82982]
6.
Beard K, Egberts T, Hallas J, Hasford J, Laporte JR, Moore N, Shakir S, Sturkenboom M. European commission consultation on pharmacovigilance. Pharmacoepidemiol Drug Saf 2008;17:108-9. [Ref.ID 82284]
7. Cita con resumen
Waller P, Shaw M, Ho D, Shakir S, Ebrahim S. Hospital admissions for "drug-induced" disorders in England: a study using the Hospital Episodes Statistics (HES) database. Br J Clin Pharmacol 2005;59:213-9. [Ref.ID 72905]
9.
Martin RM, Dunn NR, Freemantle S, Shakir S. The rates of common adverse events reported during treatment with proton pump inhibitors used in general practice in England: cohort studies. Br J Clin Pharmacol 2000;50:366-72. [Ref.ID 53002]
10.Tiene citas relacionadas Cita con resumen
Mann RD, Pearce G L, Dunn N, Shakir S. Sedation with "non-sedating" antihistamines: four prescription-event monitoring studies in general practice. BMJ 2000;320:1184-7. [Ref.ID 50668]
11. Cita con resumen
Dunn N, Wilton L, Shakir S. Stevens-Johnson syndrome and antiepileptics. Lancet 1999;354:1033-4. [Ref.ID 46934]
Seleccionar todas
 
 1 a 11 de 11